艾昆纬-炎症性肠病治疗呈上升趋势（英）

White PaperInflammatory Bowel Disease Therapeutics on the Rise IQVIA Pipeline Link/Trial Link — September 2025.SWATI S KUMAR, Senior Insights Analyst, Pipeline Link/Trial Link, IQVIA VARUN BAJAJ, Insights Associate, Pipeline Link/Trial Link, IQVIATable of contentsIntroduction 1Current treatment options 2Ulcerative colitis & Crohn’s disease clinical trial landscape 2Pipeline landscape for ulcerative colitis and Crohn’s disease 4Novel therapies in early development 6Summary 6About the authors 6References 7 iqvia.com | 1The evolving pipeline and clinical trial landscape in ulcerative colitis and Crohn’s diseaseInflammatory bowel disease (IBD) refers to a group of conditions characterized by swelling and inflammation of the tissues in the digestive tract. It is an autoimmune disorder that typically appears as a sudden flare-up of symptoms. Most cases are diagnosed in individuals aged 35 years or younger, with a second peak of diagnosis occurring in individuals in their 60s.1 Globally, the highest rates of IBD prevalence and incidence are observed in Northern Europe and North America. The 2 main types include ulcerative colitis (UC) and Crohn’s disease (CD). UC is an idiopathic inflammatory condition which is characterized by chronic inflammation of the colon, leading to diffuse friability, superficial erosions, and associated rectal bleeding. It is the most common form of IBD with a prevalence of 156 to 291 cases per 100,000 population and can affect any part of the large intestine. The primary symptom is bloody diarrhea, with or without mucus. Associated symptoms also include urgency or tenesmus, abdominal pain, malaise, weight loss, and fever.2 CD most commonly affects the small intestine and proximal colon but can affect any part of the gastrointestinal tract from the mouth to the anus. The primary symptoms include persistent diarrhea, rectal bleeding and abdominal cramps.3 CD has a prevalence of 100 to 300 per 100,000 population.4 Compared to CD, UC has a higher prevalence in adults. In the pediatric population; however, UC is less prevalent than CD. Current research highlights the following key areas in IBD pathogenesis: immune dysregulation; genetic alterations; microbiota imbalances; microbial infections; and links between IBD and other inflammatory conditions. These collectively lead to intestinal damage and chronic inflammation.5This article provides an update on current treatment options for UC and CD, outlining the latest developments including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link. IntroductionGlobally, the highest rates of IBD prevalence and incidence are observed in Northern Europe and North America. 156PROGRAMS ARE IN DEVELOPMENT FOR IBD2 | Inflammatory Bowel Disease Therapeutics on the RiseCurrent treatment optionsTreatment for UC and CD involves a comprehensive approach which includes the use of medication, alterations in diet and nutrition